welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Cardiac Magnetic Resonance in Children With Muscular Dystrophy
study id #: NCT01081080
condition: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
This protocol will exploit novel state of the art cardiovascular magnetic resonance techniques to examine important changes in the heart in children with muscular dystrophy. The purpose of this study is to compare cardiac magnetic resonance (CMR) with the collected cardiac outcome data obtained in protocol: PITT1109 – Cardiac Outcome Measures in Children with Muscular Dystrophy.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: April 2010
estimated completion: October 2011
size / enrollment: 20
Participant enrolled in the CINRG study: PITT1109 - Cardiac Outcome Measures in Children with Muscular Dystrophy
• Pregnant woman (when uncertain, participants will undergo urine testing) or lactating women
• Decompensated congestive heart failure (unable to lie flat during CMR)
• Impaired renal excretory function (calculated Glomerular Filtration Rate less than 30mL/min)
• Contra-indications to Magnetic Resonance Imaging:
-Cardiac pacemaker or implantable defibrillator
-Cerebral aneurysm clip
-Metallic ocular foreign body
-Any implanted device (i.e. insulin pump, drug infusion device)
-Metal shrapnel or bullet
Catabasis Quarterly: Updates on edasalonexent and clinical trialsHappy New Year! As 2019 kicks off, our P...
Whole Body Vibration Therapy in Boys With Duchenne Muscular DystrophyWhole-body vibration therapy (WBVT) is a...
Quantitative EMG in Duchenne Muscular DystrophyObjective: Multi-motor unit analysis (M...
Rare diseases require unique approaches in clinical trial designThere are 7,000 known rare diseases and ...
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to determin...
Study of SRP-4045 and SRP-4053 in DMD PatientsThe main objective of this study is to e...
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...